Posted by Michael Wonder on 20 Jul 2017
Proposal to change aripiprazole access and brand
20 July 2017 - PHARMAC proposes two key changes to the funding of aripiprazole tablets, an antipsychotic medicine for use in treating schizophrenia and bipolar I disorder.
The funded brand would change from Abilify (supplied by Otsuka) to Aripiprazole Sandoz (supplied by Novartis). Aripiprazole Sandoz would be the only funded brand in both the community and hospital settings.
The Special Authority and hospital restrictions currently applying to aripiprazole tablets would be removed.
Listing of Aripiprazole Sandoz on the Pharmaceutical Schedule would occur as soon as practicable following Medsafe approval.
